AstraZeneca Gets EU Approval for Breast Cancer Treatment
20 Januar 2021 - 8:48AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Wednesday that Enhertu has been granted
conditional approval by the EU as a monotherapy for the treatment
for breast cancer.
The U.K. pharmaceuticals giant said the approval was based on
positive results from the single-arm DESTINY-Breast01 Phase II
trial. The company said Enhertu showed "clinically meaningful and
durable antitumor activity in patients with HER2-positive
metastatic breast cancer who had received two or more prior
anti-HER2-based regimens."
The company has developed Enhertu--a HER2-directed antibody drug
conjugate-- in collaboration with Japan's Sankyo Co. The company
said that following EU approval the Japanese company is due a
$75-million payment from AstraZeneca as a milestone payment for
HER2.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
January 20, 2021 02:33 ET (07:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024